Cargando…

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations

Advances in molecular biology and neuroscience have led to the discovery of calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide that plays a critical role in the pathogenesis of migraine. CGRP receptor antagonist, also known as gepant, is an oral medication that inhibits the CGRP-re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Fred, Yuan, Hsiangkuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043257/ https://www.ncbi.nlm.nih.gov/pubmed/35493707 http://dx.doi.org/10.2147/TCRM.S348724

Ejemplares similares

Atogepant for the prevention of episodic migraine in adults
por: Switzer, Maranda Paige, et al.
Publicado: (2022)

Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety
por: Lattanzi, Simona, et al.
Publicado: (2022)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
por: Tao, Xinyu, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
por: Schwedt, Todd J, et al.
Publicado: (2021)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Novel Therapeutic Targets for Migraine
por: Nisar, Areeba, et al.
Publicado: (2023)

Sex and Gender Considerations in Episodic Migraine
por: Ahmad, Sarah R., et al.
Publicado: (2022)

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
por: Min, K. Chris, et al.
Publicado: (2020)

Update of Neuromodulation in Chronic Migraine
por: Yuan, Hsiangkuo, et al.
Publicado: (2021)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
por: Ashina, Messoud, et al.
Publicado: (2023)

The acute and preventative treatment of episodic migraine
por: Miller, Sarah
Publicado: (2012)

Management considerations in the treatment of migraine in adolescents
por: Matarese, Christine A, et al.
Publicado: (2010)

Pediatric migraine and episodic syndromes that may be associated with migraine
por: Spiri, Daniele, et al.
Publicado: (2014)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020)

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
por: Wu, Maximillian S, et al.
Publicado: (2022)

A Clinical Consideration of Migraine
por: Litchy, John A.
Publicado: (1917)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
por: Root, Shane, et al.
Publicado: (2023)

Efficacy and Tolerability of STOPAIN for a Migraine Attack
por: St. Cyr, Andrea, et al.
Publicado: (2015)

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Vestibular migraine: the most frequent entity of episodic vertigo
por: Dieterich, Marianne, et al.
Publicado: (2016)

Pediatric Episodic Migraine with Aura: A Unique Entity?
por: Shapiro, Hannah F.J., et al.
Publicado: (2021)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Episodic Migraine and Older Adults
por: Riggins, Nina, et al.
Publicado: (2022)

Interventional Procedures in Episodic Migraine
por: Plato, Brian M., et al.
Publicado: (2020)

Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations: A Narrative Review
por: Ailani, Jessica, et al.
Publicado: (2022)

Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine
por: Ashina, Messoud, et al.
Publicado: (2021)

Clinical considerations preliminary to application of the Italian Society for the Study of Headache's guidelines regarding migraine prophylactic treatment
por: Sternieri, Emilio, et al.
Publicado: (2003)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

Glucose-Related Traits and Risk of Migraine—A Potential Mechanism and Treatment Consideration
por: Islam, Md Rafiqul, et al.
Publicado: (2022)

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations
por: Barbanti, Piero, et al.
Publicado: (2017)

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Migraine with benign episodic unilateral mydriasis
por: Skeik, Nedaa, et al.
Publicado: (2011)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
por: Carmona, Sergio, et al.
Publicado: (2009)

Strategies of care for acute treatment of migraine
por: Tepper, Stewart J., et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_e4ppbodh1si9ru9d7s0pr88k5j